Search

CX516

NV1020

NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.

Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen

AGS-004

This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment.

Saposin C

BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. … Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy.

SynOV1.1

SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. … SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).

Probiorinse

[L16368] This strain of bacteria is said to have salubrious effects on the microbiome of the nasal cavity and sinuses.[A220193] … Probiorinse is an intranasal probiotic treatment composed of a pre-mixed and buffered sinus irrigation solution that contains the probiotic bacteria Lactococcus lactis W136.

Allocetra

With infusion, the body's macrophages and dendritic cells can feed on these early apoptotic Allocetra cells and thus result in the macrophages and dendritic cells releasing fewer cytokine alert signals … Allocetra is a novel therapy where billions of early apoptotic cells are infused into the bloodstream of a patient, using the body's own natural regulation mechanisms to rebalance an unbalanced immune

Light green SF yellowish

Light green SF yellowish is a green triarylmethane dye that is used in the preparation of the staining solution which is widely used as a counterstain. … It is used in histological applications and other labratory settings, and usually exists as a disodium salt. The maximum absorption of light green SF yellowish is at 630 (422) nm.

Fasedienol

PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder). It is a member of a new family of pharmaceutical compounds called vomeropherins.